



Supplementary information, Fig. S14


a




b




c




d



e



f



Supplementary information, Fig. S14 The LINE-1 inhibitor EFV sensitizes tumors with diverse subclones and enhances anti-PD-1 treatment efficacy in TNBC.

a Schematic representation showcasing the influence of EFV on PDX models with different subclones. **b** Growth curves of various PDXs treated with or without EFV in NSG mice (n = 5 mice/group). **c** Rate of tumor volume inhibition across different PDXs (n = 5). **d** Flow chart of the PDTF collection, culture and analysis strategy. **e** Delta values of the T-cell activation markers ICOS, CD137 and CD25 between the treated and untreated conditions in tumors with the high ITH (n = 3) and low ITH (n = 3). **f** Delta values of the cytotoxic marker IFN- γ between the treated and untreated conditions in tumors with high ITH (n = 3) and low ITH (n = 3). P values were determined using two-way ANOVA (**b**), two-tailed unpaired (**c**) and paired (**e**, **f**) Student's t tests. ns, not significant; *p < 0.05; ***p < 0.001.